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CC BY-NC-ND license (http://creativeBackground/purpose: Polyomavirus BK (BKV) reactivation causes allograft dysfunction in some
kidney transplant recipients. The use of mammalian target of rapamycin (mTOR) inhibitor-
based immunotherapy is associated with a lower incidence of polyomavirus-associated ne-
phropathy compared with other immunosuppressants. This retrospective study assessed
whether conversion to mTOR inhibitor-based immunotherapy directly reduced urinary BKV
load.
Methods: A total of 63 kidney recipients were divided into mTOR inhibitor-conversion (21 pa-
tients) and nonconversion (42 patients) groups. Urinary BKV loads were determined before and
at least 6 months after the conversion.
Results: The results demonstrated that urinary BKV titer was significantly reduced in the con-
version group (3.94  0.43 copies (log)/mL to 2.49  0.19 copies (log)/mL) and remained un-
altered in the nonconversion group (3.19  0.20 copies (log)/mL to 2.90  0.20 copies (log)/
mL). In addition, the percentage of patients with reduced urinary BKV load was significantlyng authors declare no conflicts of interest.
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540 C.-L. Yen et al.higher in the conversion group (76.2% vs. 42.9%). The estimated glomerular filtration rate after
24 months mTOR inhibitor conversion was significantly increased compared with that in the
nonconversion group. Conversion to mTOR-inhibitor-based immunotherapy was the only factor
associated with an increase in estimated glomerular filtration rate.
Conclusion: This study reveals an association of conversion to mTOR-inhibitor-based immuno-
therapy with the reduction of urinary BKV load.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Polyomavirus-associated nephropathy (PVAN) has been re-
ported in different transplant centers worldwide.1e3
Because of the lack of early symptoms and signs, early
diagnosis of PVAN is frequently overlooked and easily
mistaken as acute rejection if polyomavirus BK (BKV)
infection is not periodically monitored.4 To date, no anti-
viral agents for treating PVAN are satisfactory, leading to a
high frequency of allograft dysfunction in kidney transplant
recipients with PVAN.5
The common standard of diagnosis depends on specific
histological findings of viral cytopathic change or positive
BKV immunostaining in allograft biopsy.4,6 However,
numerous noninvasive tests have been adopted for early
identification of BKV infection in kidney transplant recipi-
ents.7e9 Although BKV viremia is more predictive of PVAN
development compared with BKV viruria, several studies
have demonstrated that BKV viruria is correlated with BKV
viremia10e12 and allograft dysfunction.1,13,14 Considering
the known latency and early reactivation of the virus in the
renourinary tract, the occurrence of BKV viruria is a
potentially sensitive marker of early viral reactivation and a
surrogate of overimmunosuppression.15e17
The effect of most anti-BKV agents such as cidofovir and
leflunomide on alleviating PVAN progression remains
controversial18,19; therefore, the current treatment strategy
is to reduce immunosuppressant dosage empirically.20
Although the net immune status of the host is the most
crucial factor for the PVAN development, some immuno-
suppressants are associated with a high incidence of BKV
viruria, viremia, and PVAN. Previous studies have demon-
strated that the use of tacrolimus compared with cyclo-
sporine and mycophenolate compared with azathioprine are
associated with a high incidence of BKV viruria, BKV viremia,
and PVAN occurrence in kidney transplant recipients.21e23 In
addition, in vitro studies have reported that specific immu-
nosuppressants such as cyclosporine can suppress BKV rep-
lication.24e26 These studies have indicated the possibility of
a direct effect of specific immunosuppressants on BKV
reactivation in addition to their immunosuppressive effects.
Mammalian target of rapamycin (mTOR) inhibitors,
including sirolimus and everolimus, are widely used to avoid
nephrotoxicity of calcineurin inhibitors (CNIs).27 Sirolimus
suppresses BKV replication in a cell culture system.28
Furthermore, mTOR-inhibitor-based immunotherapy is
associated with a low risk of active reactivation status,
including BKV viremia and PVAN in kidney transplant re-
cipients.29,30 However, these reports did not establish acauseeeffect relationship, showing alteration of BKV load
following conversion to mTOR-inhibitor-based immunosup-
pressants. Therefore, although mTOR-inhibitor-based
immunotherapy is likely associated with a lower risk of
BKV viremia and PVAN occurrence, whether conversion to
mTOR-inhibitor-based immunotherapy directly leads to a
reduction in urinary BKV load, even in less active viral
replication status, requires further investigation. The aim
of the current study was to determine whether conversion
to mTOR-inhibitor-based immunotherapy was associated
with reduced urinary BKV load.Methods
Patients
A total of 63 kidney recipients were enrolled in this retro-
spective observational study. This retrospective study was
conducted with the permission of the Ethics Committee of
our hospital. Only patients who underwent urinary BKV load
screen tests on two urine samples obtained separately by at
least 6 months from January 2006 to January 2014 were
included. Patients who received mTOR inhibitors (sirolimus
or everolimus) at the time of enrolment were excluded.
The immunosuppressive regimen was converted to mTOR-
inhibitor-based immunotherapy with CNIs minimization or
elimination 6e18 months after kidney transplantation to
reduce CNI nephrotoxicity and the incidence of malignancy.
In the conversion to mTOR-inhibitor-based immunotherapy
group, initial doses of sirolimus and everolimus were 2 mg/
d and 0.75 mg twice daily, respectively. The doses of siro-
limus and everolimus were adjusted weekly to reach the
target trough levels of 3e6 ng/mL for sirolimus and 3e5 ng/
mL for everolimus. The CNI doses were concurrently
reduced to reach the target trough levels of 50e100 ng/mL
for cyclosporine and 3e5 ng/mL for tacrolimus at 1 month
after administration of mTOR inhibitions (CNI minimiza-
tion). In kidney recipients receiving the conversion to CNI-
free mTOR-inhibitor-based immunotherapy (CNI elimina-
tion), the target trough levels of sirolimus and everolimus
were 5e10 ng/mL and 5e8 ng/mL, respectively. In the
nonconversion group, the target trough levels of CNIs were
maintained as 100e200 ng/mL for cyclosporine and
5e10 ng/mL for tacrolimus. Mycophenolate/azathioprine
and steroids were mostly unaltered or adjusted according
to clinical condition.
Urine BKV titer was quantified using a quantitative po-
lymerase chain reaction (qPCR). Serum creatinine levels
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The estimated glomerular filtration rate (eGFR) was
calculated using the CockcrofteGault formula. The de-
mographic and clinical data were recorded when the pa-
tients were enrolled.
Quantitative measurement of urine BKV
DNA was extracted from 200 mL of urine using the QIAmp
DNA Mini Kit (Qiagen, Hilden, Germany). In addition, qPCR
was performed on an ABI-Prism 7700 using SYBR Green I as a
double-stranded DNA-specific dye (PE-Applied Biosystems,
Warrington, Cheshire, UK). Glyceraldehyde-3-phosphate
dehydrogenase was used as a standard housekeeping
gene. Primers (BKV: sense 50-CTGTCCCTAAAACCCTGCAA-30
and antisense 50-GCCTTTCCTTCCATTCAACA-30) were con-
structed to be compatible with a single reverse transcrip-
tase PCR thermal profile (95C for 10 minutes, 40 cycles of
95C for 30 seconds and 60C for 1 minute). PCR product
accumulation was monitored in real time (PE-Applied Bio-
systems). The copy numbers of BKV were calculated based
on the standard curve described in the subsequent para-
graph. The assay showed a wide linear range of 10e109
copy equivalents of viral DNA, and the limit of detection
was 10 copies/mL BKV DNA.
The BKV large T antigen fragment was amplified from
BKV obtained from the American Type Culture CollectionTable 1 Demographic and laboratory characteristics of patie
immunotherapy.
Parameter Conversion
(n Z 21)
Male (male) 11 (52.4%)
Age (y) 48.43  10.33
Body weight (kg) 61.43  11.43
Living donor 3 (14.3%)
DM 4 (19%)
HBV 2 (9.5%)
HCV 4 (19%)
Hct (%) 38.26  5.47
WBC (103/dL) 6.64  2.39
Platelet (103/dL) 191.43  64.13
ALT 27.71  16.08
Serum creatinine 1.37  0.94
eGFR (mL/min) 64.75  27.38
Use of immunosuppressants at the first test
Cyclosporine 7 (33.3%)
Tacrolimus 14 (66.7%)
MMF 13 (61.9%)
Azathioprine 1 (4.8%)
Steroid 18 (85.7%)
Use of immunosuppressants at the end of follow up
Cyclosporin 5 (23.8%)
Tacrolimus 9 (42.9%)
MMF 15 (71.4%)
Azathioprine 1 (4.8%)
Steroid 16 (76.2%)
ALT Z alanine aminotransferase; DM Z diabetes mellitus; eGFR Z
Hct Z hematocrit; HCV Z hepatitis C virus; MMF Z mycophenolat
significant; WBC Z white blood cell count.(CCL-137; Manassas, VA, USA) and was cloned using the
TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, USA). The
plasmids containing BKV fragments were amplified and
purified using the Genopure Plasmid Midi Kit (Roche, Man-
nheim, Germany). Plasmid DNA concentrations were
determined using optical density measurement at 260 nm.
The copy numbers of BKV plasmids were calculated using
the following formula: m Z n  1.096 1021 g/bp
M Z m  copy number of interest, where n is the plasmid
size (bp), m is the mass of DNA, and M is the mass required
for obtaining the copy number of interest. The BKV plasmid
DNA was serially diluted in a logarithmic manner to obtain
107e109 copies per sample load (5 mL) for standard curve
establishment. The correlation value of the standard curve
was limited to 0.995 < g2 < 1.
Statistical analysis
All of the data were presented as mean  standard error.
The KolmogoroveSmirnov test was used to test all variables
for normal distribution. For normal distribution variables,
Student’s t test was used, and the ManneWhitney U test
was applied for the variables without normal distribution.
Pearson’s c2 test was applied to analyze categorical vari-
ables. Comparisons of eGFR during follow up were made by
repeated-measurement analysis of variance using the gen-
eral linear model procedure. Logistic regression analysisnts with and without conversion to mTOR-inhibitor-based
Nonconversion
(n Z 42)
p
19 (45.2%) NS
49.79  8.06 NS
59.51  9.83 NS
2 (4.8%) NS
8 (19%) NS
6 (14.3%) NS
9 (21.4%) NS
37.72  5.46 NS
6.62  2.52 NS
202.05  64.33 NS
23.80  18.35 NS
1.62  1.10 NS
54.57  24.66 NS
22 (52.4%) NS
19 (45.2%) NS
28 (66.7%) NS
0 (0%) NS
33 (78.6%) NS
17 (40.5%) NS
24 (57.1%) NS
31 (73.8%) NS
1 (2.4%) NS
30 (71.4%) NS
estimated glomerular filtration rate; HBV Z hepatitis B virus;
e mofetil; mTOR Z mammalian target of rapamycin; NS Z not
Figure 1 Conversion to mTOR-inhibitor-based immunotherapy
reduced urinary BKV load. Urinary BKV load (copies/mL) at base-
line and follow up in the mTOR-inhibitor-conversion (black bars)
and nonconversion (white bars) groups was determined using
quantitative polymerase chain reaction. Differences in urinary
BKV titers at baseline and followupwere analyzed using a paired t
test, and p  0.05 was not significant (NS). BKVZ polyomavirus
BK; mTORZmammalian target of rapamycin.
Figure 2 Conversion to mTOR-inhibitor-based immuno-
therapy yielded a high percentage of patients with decreased
urinary BKV load. The percentage of patients who had a
decrease in urinary BKV load at follow up compared with that
at baseline was calculated. A significant difference in the
percentage of patients with a decreased BKV titer in the mTOR-
inhibitor-conversion (black bar) and nonconversion (white bar)
groups was observed (p Z 0.021). BKV Z polyomavirus BK;
mTOR Z mammalian target of rapamycin.
542 C.-L. Yen et al.combined with a log-rank test was used to calculate the
factors corresponding to an increase in eGFR at 24 months
compared with baseline eGFR. A p value < 0.05 was
considered to represent a significant difference.
Results
Patients
This retrospective observational study enrolled 63 kidney
recipients who underwent urinary BKV load screen tests on
two urine samples obtained separately by at least 6 months
from 2006 to 2014. The patients were divided into two
groups according to whether they received conversion to
mTOR-inhibitor-based (sirolimus or everolimus) immuno-
therapy. From the 21 patients who received mTOR inhibitor
conversion, two urine samples were obtained separately for
BKV viruria screening before and at least 6 months after the
conversion. In the nonconversion group, the 42 patients did
not take any mTOR inhibitor throughout the study. They
received the second BKV viruria screening at least 6 months
after the first BKV viruria test. The period from trans-
plantation to the first measurement of BKV viruria and the
interval between two measurements of BKV viuria in the
two groups did not differ significantly (data not shown).
Demographic data revealed no statistically significant dif-
ference in sex, age, prevalence of diabetes mellitus, hep-
atitis B, hepatitis C, or donor type (Table 1). In addition, no
statistically significant difference in the initial immuno-
suppressant regimens was observed. None of the 63 pa-
tients were administered mTOR inhibitors when enrolled inthis study. None of these patients had received induction
therapy before. At the first measurement of BKV viruria,
CNIs, mycophenolate, and steroid use did not differ be-
tween the two groups. At the second measurement, 33% of
the patients did not receive CNIs (CNI elimination) and 67%
of the patients in the conversion group received a low dose
of CNIs (CNI minimization) combined with mTOR inhibitors,
whereas 98% of the patients in the nonconversion group
received a normal dose of CNIs (p < 0.05). The average
trough level of cyclosporine in the nonconversion group was
141.3 ng/mL, and that of tacrolimus in the nonconversion
group was 6.9 ng/mL. The average trough level of cyclo-
sporine before and after mTOR inhibitor conversion in the
CNI minimization subgroup was 181.3 ng/mL and 65.4 mg/
mL, respectively. The average trough level of tacrolimus
before and after mTOR inhibitor conversion in this subgroup
was 6.5 ng/mL and 3.1 ng/mL, respectively. In the CNI
elimination subgroup, the average trough level of cyclo-
sporine before conversion to mTOR inhibitor was 135.2 ng/
mL and that of tacrolimus was 8.9 ng/mL.
No difference in hematocrit level, white blood cell
count, platelet count, serum creatinine level, eGFR, and
alanine aminotransferase levels were observed between
the two groups.
Conversion to mTOR-inhibitor-based
immunotherapy reduced BKV viruria load
The baseline urinary BKV titer in the conversion group was
higher than that in the nonconversion group (Figure 1).
During follow up, the second urinary BKV titer in the
Table 2 Factors associated with a decrease in urinary polyomavirus BK load.
Parameter b coefficient SE OR (95%CI) p
Univariate logistic regression
Sex 0.588 0.511 0.556 (0.204e1.512) NS
DM 0.732 0.673 0.481 (0.128e1.799) NS
Age (y) 0.009 0.029 1.009 (0.954e1.068) NS
BW (kg) 0.050 0.026 1.052 (0.999e1.107) NS
Hct (%) 0.098 0.051 1.103 (0.999e1.218) NS
HBV 1.135 0.860 0.321 (0.060e1.734) NS
HCV 0.891 0.664 0.410 (0.112e1.508) NS
Cyclosporine 0.427 0.531 0.652 (0.230e1.848) NS
Tacrolimus 0.329 0.507 0.720 (0.266e1.944) NS
MMF 0.357 0.574 0.700 (0.227e2.157) NS
Steroid 0.619 0.576 1.857 (0.601e5.739) NS
Conversion to mTOR inhibitors 1.549 0.601 4.706 (1.449e15.286) 0.010
BW Z body weight; CI Z confidence interval; DM Z diabetes mellitus; HBVZ hepatitis B virus; Hct Z hematocrit; HCVZ hepatitis C
virus; MMF Z mycophenolate mofetil; NS Z not significant; OR Z odds ratio; SE Z standard error.
Figure 3 An increase in the eGFR value during 24 months
follow up in the mTOR-inhibitor-conversion group. Serum
creatinine levels in the mTOR-inhibitor-conversion and non-
conversion groups were recorded every 6 months during
24 months follow up. eGFR was calculated using the Cock-
crofteGault formula every 6 months in the conversion (dash
line) and nonconversion (solid line) groups, and was analyzed
using repeated measurement analysis of variance. The star sign
indicates the significant difference of the eGFR level.
eGFR Z estimated glomerular filtration rate;
mTORZ mammalian target of rapamycin; NSZ not significant
(p > 0.05).
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copies (log)/mL to 2.90  0.20 copies (log)/mL, p: no sig-
nificance], whereas that in the conversion group was
significantly reduced [3.94  0.43 copies (log)/mL to
2.49  0.19 copies (log)/mL, p Z 0.003].
To verify that urinary BKV load was commonly reduced in
the conversion group, we analyzed the percentage of pa-
tients who had a decrease in the urinary BKV load at follow
up compared with the urinary BKV load at baseline
(Figure 2). The percentage of patients exhibiting a
decreased BKV titer was significantly higher in the conver-
sion group compared with the nonconversion group (76.2%
vs. 42.9%, p Z 0.021). We further stratified the conversion
group into the conversion to mTOR inhibitors with CNI
minimization subgroup and the conversion to mTOR in-
hibitors with CNI elimination subgroup. The result revealed
that the percentage of patients with decreased BKV load in
either the CNI minimization or elimination group was
significantly higher than that in nonconversion group (71.4%
vs. 42.9%, p Z 0.045; 85.7% vs. 42.9%, p Z 0.026). There
was no significant difference in percentage of patients with
decreased urinary BKV load between the CNI minimization
and CNI elimination groups (71.4% vs. 85.7%, p Z 0.469).
These results suggested that conversion to mTOR-inhibitor-
based immunotherapy was significantly associated with a
reduction in urinary BKV load.
To determine the factors associated with decreased
urine BKV titer, logistic regression analysis was used. The
results demonstrated that conversion to mTOR-inhibitor-
based immunotherapy was the only independent risk factor
for decreased urinary BKV load (Table 2).
Conversion to mTOR-inhibitor-based
immunotherapy reduced the risk of renal function
decline
Several studies have demonstrated that conversion to
mTOR-inhibitor-based immunotherapy substantially atten-
uates renal function decline.31e33 To determine whether
decreased urinary BKV load following conversion to mTOR
inhibitors ameliorates renal function, eGFR in both groupswas analyzed every 6 months. As shown in Figure 3, eGFR
during 24 months follow up in the conversion group was
increased when compared with baseline eGFR
(64.8  6.0 mL/min vs. 70.2  7.2 mL/min, p Z 0.04). In
contrast, eGFR during 24 months follow up in the non-
conversion group did not differ significantly from baseline
eGFR (54.6  3.9 mL/min vs. 54.0  3.6 mL/min, p > 0.05).
We previously demonstrated that urinary BKV load was
associated with renal function alteration during 12 months
follow up.1 As conversion to mTOR inhibitors was associated
544 C.-L. Yen et al.with a reduction in urinary BKV load and an increase in
eGFR, we further analyzed the factors associated with an
increase in eGFR. Logistic regression analysis showed that
conversion to mTOR inhibitors was the only independent
factor negatively associated with an increase in eGFR
(Table 3). These results suggested that in addition to an
association with reduced urinary BKV load, conversion to
mTOR inhibitors was also associated with increased renal
function during 24 months follow up.Discussion
Several risk factors associated with PVAN development
have been identified in previous studies.34 Among the risk
factors, using highly potent immunosuppressants such as
tacrolimus is associated with a high risk of BKV viruria,
viremia, and PVAN development.35,36 Because no satisfac-
tory anti-BKV treatment is currently available, early
detection of BKV infection reactivation is fundamental in
preventing PVAN development. We and others have previ-
ously demonstrated that the early detection of BKV infec-
tion by screening urinary BKV load is an effective approach
for predicting renal function deterioration.11,12,37 mTOR
inhibitors are widely used to prevent CNI nephrotoxicity
and reduce malignancy in transplant recipients. Several
studies have reported a lower incidence of PVAN in patients
receiving mTOR-inhibitor-based immunotherapy.38e40
However, alteration of urinary BKV load after conversion
to mTOR-inhibitor-based immunotherapy has not been
analyzed. In this study, we demonstrated that conversion to
mTOR-inhibitor-based immunotherapy was associated with
reduced urinary BKV load.
An in vitro study showed that sirolimus suppresses the
expression of BKV T antigen in both immortalized human
renal cells and primary human renal tubular cells through
the inhibition of the protein kinase Akt/mTOR pathway.28 In
humans, Dharnidharka et al39 reported a significantly lower
2-year cumulative incidence of anti-BKV treatment inTable 3 Factors for an increase in estimated glomerular filtrat
Parameter b coefficient SE
Univariate logistic regression
Sex 0.966 0.
DM 0.020 0.
Age (y) 0.033 0.
BW (kg) 0.027 0.
Urinary BKV load 0.633 0.
Hct (%) 0.055 0.
HBV 0.405 0.
HCV 0.251 0.
Cyclosporine 0.616 0.
Tacrolimus 0.100 0.
MMF 0.324 0.
Steroid 0.344 0.
mTOR inhibitor 1.288 0.
BKV Z polyomavirus BK; BW Z body weight; CI Z confidence
Hct Z hematocrit; HCV Z hepatitis C virus; MMF Z mycophenolat
significant; OR Z odds ratio; SE Z standard error.kidney transplant recipients receiving mTOR-inhibitor-
based therapy compared with those on other regimens
without mTOR inhibitors. A retrospective study demon-
strated that six of 344 (1.7%) kidney transplant recipients
receiving sirolimus-based immunotherapy had biopsy-
confirmed PVAN at a mean follow up of 43 months, which
was significantly lower than with other immunosuppressive
regimens.38 Nevertheless, these studies have analyzed an
association between mTOR inhibitor use and the incidence
of PVAN but have not directly assessed the alteration of BKV
load after conversion to mTOR-inhibitor-based immuno-
therapy. Our study verified the findings of cell culture ex-
periments and clinical retrospective studies in that mTOR-
inhibitor-based immunotherapy reduced the risk of PVAN
development. Because early suppression of BKV replication
is crucial to preventing PVAN development, our study sug-
gests that conversion to mTOR-inhibitor-based immuno-
therapy is favorable in reducing urinary BKV load, even in
patients exhibiting a low titer of BKV viruria.
Conversion to mTOR-inhibitor-based immunotherapy has
been shown to improve renal function. Our study also
demonstrated that conversion to mTOR-inhibitor-based
immunotherapy was the only factor associated with an in-
crease in eGFR. The beneficial effect of reduced urinary
BKV load on renal function preservation was outcompeted
by the major determining factor, that is, conversion to
mTOR-inhibitor-based immunotherapy for CNI nephrotoxi-
city prevention. In addition, whereas other studies have
revealed a negative association between mTOR inhibitor
use and impaired renal function caused by PVAN, a severe
form of BKV infection,38,40 our patients who had less severe
BKV infection still revealed reduction of urinary BKV load
following mTOR inhibitor conversion. The beneficial effect
of reduced urinary BKV load on renal function preservation
in this study may require a longer observation period.
Our study could not identify whether the beneficial ef-
fect of conversion to mTOR-inhibitor-based immunotherapy
on reduction of urinary BKV load was attributed to the use
of mTOR inhibitors or elimination/minimization of CNIs, asion rate after 24 months follow up.
OR (95% CI) p
527 2.629 (0.936e7.380) NS
651 0.980 (0.274e3.510) NS
030 1.033 (0.974e1.096) NS
025 1.027 (0.977e1.079) NS
521 1.882 (0.678e5.225) NS
049 1.056 (0.960e1.162) NS
759 0.667 (0.151e2.950) NS
627 0.778 (0.228e6.257) NS
555 1.851 (0.624e5.488) NS
513 0.905 (0.331e2.472) NS
572 1.383 (0.451e4.244) NS
588 0.709 (0.224e2.246) NS
560 3.625 (1.210e10.859) 0.021
interval; DM Z diabetes mellitus; HBV Z hepatitis B virus;
e mofetil; mTOR Z mammalian target of rapamycin; NS Z not
mTOR inhibitor reduces urinary BKV load 545conversion to mTOR inhibitors is commonly accompanied by
minimization/elimination of CNIs. Therefore, our study
displays an advantage of treatment strategy using conver-
sion to mTOR-inhibitor-based immunotherapy in reduction
of urinary BKV titer but does not necessarily exclude
attribution of CNI minimization/elimination to this
advantage.
One limitation of this study was the retrospective design
in which the patients were not randomly divided for anal-
ysis. In addition, the case number was relatively low and
the beneficial effect of reduced urinary BKV load on renal
function preservation requires verification by large- and
longer follow-up studies. Furthermore, the enrolled pa-
tients did not have severe BKV infections such as BKV
viremia and PVAN. Nevertheless, this study provided direct
evidence suggesting that conversion to mTOR-inhibitor-
based immunotherapy with CNI minimization or elimina-
tion as a whole treatment strategy reduces urinary BKV
load, even in patients with mild BKV infection.
In conclusion, this study revealed a beneficial effect of
conversion to mTOR-inhibitor-based immunotherapy on
urinary BKV load reduction in kidney transplant recipients.Acknowledgments
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